Table 6: Pathways affected by negatively correlated gene targets identified in table 4.
The target gene-list from table 5 was input in the Ingenuity Pathway Analysis with fold change data at each dose-point and time-point (2 Gy, 4 Gy and 8 Gy at 24 h and 48 h time-points compared to 0 Gy controls). IPA computes z-scores and p-values. The significantly affected pathways are listed here along with corresponding -log (p values) and the genes (from target list in table 5) involved in the corresponding pathway.
| Ingenuity Canonical Pathways | -log (p-value) | Molecules Associated |
|---|---|---|
| Molecular Mechanisms of Cancer | 11.5 | MAPK14,AKT3,FYN,CCND1,CDKN1A,RHOC,MAP2K3,JAK1,MDM2,BMP2,FAS |
| p53 Signaling | 9.77 | MAPK14,AKT3,CCND1,CDKN1A,MDM2,TP53INP1,FAS |
| Pancreatic Adenocarcinoma Signaling | 7.8 | STAT3,AKT3,CCND1,CDKN1A,JAK1,MDM2 |
| IL-22 Signaling | 7.46 | MAPK14,STAT3,AKT3,JAK1 |
| Tec Kinase Signaling | 6.9 | STAT3,FYN,TNFSF12,RHOC,JAK1,FAS |
| Oncostatin M Signaling | 6.83 | STAT3,TIMP3,JAK1,EPAS1 |
| IL-7 Signaling Pathway | 6.76 | MAPK14,AKT3,FYN,CCND1,JAK1 |
| Acute Myeloid Leukemia Signaling | 6.71 | STAT3,AKT3,CCND1,RUNX1,MAP2K3 |
| AMPK Signaling | 6.29 | ULK1,MAPK14,AKT3,CCND1,CDKN1A,MAP2K3 |
| HIF1α Signaling | 6.2 | MAPK14,AKT3,SLC2A3,EGLN3,MDM2 |
| PI3K/AKT Signaling | 6.07 | AKT3,CCND1,CDKN1A,JAK1,MDM2 |
| Melanoma Signaling | 5.97 | AKT3,CCND1,CDKN1A,MDM2 |
| Colorectal Cancer Metastasis Signaling | 5.94 | STAT3,AKT3,TLR7,CCND1,RHOC,JAK1 |
| EGF Signaling | 5.6 | MAPK14,STAT3,AKT3,JAK1 |
| IL-10 Signaling | 5.57 | MAPK14,STAT3,MAP2K3,JAK1 |
| Glioblastoma Multiforme Signaling | 5.52 | AKT3,CCND1,CDKN1A,RHOC,MDM2 |
| GM-CSF Signaling | 5.47 | STAT3,AKT3,CCND1,RUNX1 |
| IL-15 Signaling | 5.4 | MAPK14,STAT3,AKT3,JAK1 |
| IL-17A Signaling in Airway Cells | 5.36 | MAPK14,STAT3,AKT3,JAK1 |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 5.36 | MAPK14,STAT3,AKT3,TLR7,CCND1,MAP2K3 |
| JAK/Stat Signaling | 5.25 | STAT3,AKT3,CDKN1A,JAK1 |
| Role of JAK family kinases in IL-6-type Cytokine Signaling | 5.24 | MAPK14,STAT3,JAK1 |
| IL-17 Signaling | 5.21 | MAPK14,AKT3,MAP2K3,JAK1 |
| HER-2 Signaling in Breast Cancer | 5.15 | AKT3,CCND1,CDKN1A,MDM2 |
| Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 5.13 | MAPK14,AKT3,CLU,RHOC,JAK1 |
| FGF Signaling | 5.09 | MAPK14,STAT3,AKT3,MAP2K3 |
| Sumoylation Pathway | 5 | DNMT3A,RHOC,MDM2,FAS |
| Prostate Cancer Signaling | 4.98 | AKT3,CCND1,CDKN1A,MDM2 |
| Mouse Embryonic Stem Cell Pluripotency | 4.83 | MAPK14,STAT3,AKT3,JAK1 |
| Chronic Myeloid Leukemia Signaling | 4.83 | AKT3,CCND1,CDKN1A,MDM2 |
| Inhibition of Angiogenesis by TSP1 | 4.83 | MAPK14,AKT3,FYN |
| Type I Diabetes Mellitus Signaling | 4.75 | MAPK14,MAP2K3,JAK1,FAS |
| Glioma Signaling | 4.71 | AKT3,CCND1,CDKN1A,MDM2 |
| HGF Signaling | 4.69 | STAT3,AKT3,CCND1,CDKN1A |
| Fc Epsilon RI Signaling | 4.63 | MAPK14,AKT3,FYN,MAP2K3 |
| Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency | 4.59 | STAT3,AKT3,JAK1,BMP2 |
| Role of Tissue Factor in Cancer | 4.58 | MAPK14,AKT3,FYN,LIMK1 |
| IL-6 Signaling | 4.51 | MAPK14,STAT3,AKT3,MAP2K3 |
| HMGB1 Signaling | 4.44 | MAPK14,AKT3,RHOC,MAP2K3 |
| Aryl Hydrocarbon Receptor Signaling | 4.34 | CCND1,CDKN1A,MDM2,FAS |
| Semaphorin Signaling in Neurons | 4.24 | FYN,LIMK1,RHOC |
| Neuroinflammation Signaling Pathway | 4.15 | MAPK14,AKT3,TLR7,JAK1,FAS |
| Acute Phase Response Signaling | 4.03 | MAPK14,STAT3,AKT3,MAP2K3 |
| Germ Cell-Sertoli Cell Junction Signaling | 4 | MAPK14,LIMK1,RHOC,MAP2K3 |
| Ephrin Receptor Signaling | 3.98 | STAT3,AKT3,FYN,LIMK1 |
| Glucocorticoid Receptor Signaling | 3.98 | MAPK14,STAT3,AKT3,CDKN1A,JAK1 |
| Cell Cycle: G1/S Checkpoint Regulation | 3.96 | CCND1,CDKN1A,MDM2 |
| Glioma Invasiveness Signaling | 3.88 | TIMP3,RHOC,TIMP2 |
| Regulation of the Epithelial-Mesenchymal Transition Pathway | 3.85 | STAT3,AKT3,MAP2K3,JAK1 |
| Role of MAPK Signaling in the Pathogenesis of Influenza | 3.84 | MAPK14,AKT3,MAP2K3 |
| STAT3 Pathway | 3.81 | MAPK14,STAT3,CDKN1A |
| TREM1 Signaling | 3.79 | STAT3,AKT3,TLR7 |
| IL-8 Signaling | 3.78 | AKT3,CCND1,LIMK1,RHOC |
| ILK Signaling | 3.78 | AKT3,CCND1,RHOC,BMP2 |
| Toll-like Receptor Signaling | 3.77 | MAPK14,TLR7,MAP2K3 |
| CD40 Signaling | 3.72 | MAPK14,STAT3,MAP2K3 |
| IL-3 Signaling | 3.66 | STAT3,AKT3,JAK1 |
| FLT3 Signaling in Hematopoietic Progenitor Cells | 3.61 | MAPK14,STAT3,AKT3 |
| PEDF Signaling | 3.6 | MAPK14,AKT3,FAS |
| TGF-β Signaling | 3.6 | MAPK14,MAP2K3,BMP2 |
| Bladder Cancer Signaling | 3.58 | CCND1,CDKN1A,MDM2 |
| Death Receptor Signaling | 3.51 | TNFSF12,LIMK1,FAS |
| Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 3.5 | MAPK14,AKT3,MAP2K3,BMP2 |
| GADD45 Signaling | 3.49 | CCND1,CDKN1A |
| ATM Signaling | 3.45 | MAPK14,CDKN1A,MDM2 |
| Cholecystokinin/Gastrin-mediated Signaling | 3.41 | MAPK14,RHOC,MAP2K3 |
| IGF-1 Signaling | 3.35 | STAT3,AKT3,JAK1 |
| Role of JAK1, JAK2 and TYK2 in Interferon Signaling | 3.28 | STAT3,JAK1 |
| Estrogen-mediated S-phase Entry | 3.21 | CCND1,CDKN1A |
| PTEN Signaling | 3.2 | AKT3,CCND1,CDKN1A |
| p38 MAPK Signaling | 3.19 | MAPK14,MAP2K3,FAS |